Skip to main content

Table 3 Results of univariate analysis of factors associated with progression-free (PFS) and overall survival (OS) rates

From: Levels of pretreatment blood lipids are prognostic factors in advanced NSCLC patients treated with anlotinib

Variable (N = 137)

PFS

OS

HR

95%CI

Univariate (P value)

HR

95%CI

Univariate (P value)

Age (years)

1.057

0.756–1.505

0.713

0.897

0.508–1.324

0.564

  < 65

      

  ≥ 65

      

Gender

1.162

0.797–1.694

0.435

1.067

0.697–1.634

0.764

 Male

      

 Female

      

Histology

1.198

0.855–1.679

0.294

1.165

0.799–1.700

0.428

 Squamous

      

 Non-squamous

      

Performance Status (ECOG)

1.168

0.810–1.584

0.405

1.453

0.975–2.165

0.066

 0–1

      

 2–3

      

Driver gene

1.002

0.663–1.515

0.993

1.147

0.726–1.811

0.557

 Wild

      

 Mutation

      

Metastasis sites

0.932

0.667–1.316

0.707

0.997

0.685–1.453

0.989

  ≤ 3

      

  > 3

      

Line(s) of treatment

1.063

0.758–1.494

0.725

0.768

0.523–1.127

0.178

 3

      

  ≥ 3

      

TG

1.689

1.152–2.475

0.007

1.431

0.949–2.159

0.088

  < 1.82

      

  ≥ 1.82

      

TC

2.647

1.655–3.777

0.000

1.773

1.213–2.592

0.003

  < 4.77

      

  ≥ 4.77

      

LDL

3.056

2.091–4.495

0.000

1.532

1.040–2.257

0.031

  < 2.965

      

  ≥ 2.965

      

HDL

1.085

0.773–1.522

0.637

0.910

0.623–1.328

0.624

  < 1.095

      

  ≥ 1.095

      
  1. The unit of measurement for lipids is mmol/L
  2. HR hazard ratio, CI confidence interval, TG triglyceride, TC total cholesterol, LDL low density lipoprotein, HDL high density lipoprotein
Back to article page

Lipids in Health and Disease

ISSN: 1476-511X